Curis, Inc. (NASDAQ:CRIS – Get Rating) – Investment analysts at HC Wainwright raised their Q1 2023 earnings per share (EPS) estimates for shares of Curis in a research note issued on Monday, March 13th. HC Wainwright analyst E. White now forecasts that the biotechnology company will earn ($0.11) per share for the quarter, up from their prior forecast of ($0.12). The consensus estimate for Curis’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Curis’ Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.42) EPS, FY2024 earnings at ($0.47) EPS and FY2025 earnings at ($0.50) EPS.
Curis (NASDAQ:CRIS – Get Rating) last announced its quarterly earnings results on Monday, March 13th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Curis had a negative net margin of 557.68% and a negative return on equity of 87.74%. The firm had revenue of $2.89 million for the quarter, compared to the consensus estimate of $3.03 million. During the same period in the prior year, the firm posted ($0.15) earnings per share.
Curis Stock Up 6.2 %
NASDAQ:CRIS opened at $0.56 on Thursday. The firm has a market capitalization of $54.04 million, a P/E ratio of -0.92 and a beta of 2.88. Curis has a 52 week low of $0.47 and a 52 week high of $2.90. The company has a fifty day moving average of $0.69 and a 200 day moving average of $0.74.
Institutional Investors Weigh In On Curis
Several large investors have recently added to or reduced their stakes in the stock. Dimension Capital Management LLC boosted its stake in shares of Curis by 18.2% during the second quarter. Dimension Capital Management LLC now owns 130,000 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 20,000 shares during the period. Virtu Financial LLC boosted its stake in Curis by 235.8% in the second quarter. Virtu Financial LLC now owns 70,848 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 49,748 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Curis in the 2nd quarter worth $59,000. UBS Group AG grew its stake in shares of Curis by 183.6% during the third quarter. UBS Group AG now owns 51,332 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 33,231 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Curis during the 1st quarter worth approximately $32,000. 38.72% of the stock is owned by institutional investors.
Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
- Get a free copy of the StockNews.com research report on Curis (CRIS)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.